INMB Q3 2022 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena

INMBINmune Bio, Inc.

$37M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$98,000+600.0% YoY

Gross Profit

$98,000100.0% margin

Operating Income

-$7M-7594.9% margin

Net Income

-$8M-7882.7% margin

EPS (Diluted)

$-0.45

QoQ Revenue Growth

+512.5%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$84M

Total Liabilities

$20M

Stockholders' Equity

$64M

Cash & Equivalents

$57M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$98,000	$14,000	+600.0%
Gross Profit	$98,000	$14,000	+600.0%
Operating Income	-$7M	-$9M	+17.5%
Net Income	-$8M	-$9M	+18.3%